| 
             
			
			 Newer, less-controversial technologies, including the 
			“reprogramming” of adult skin cells to create specific types of stem 
			cells, have rendered fetal tissue less central - though still 
			important - to medical research, they said. 
			 
			Dr. Robert Lanza, chief scientific officer of Advanced Cell 
			Technology, said that much of tissue needed for research "can now be 
			generated in the laboratory." 
			 
			At Massachusetts General Hospital in Boston, for instance, only 
			about 10 out of 8,000 active research protocols involve fetal 
			tissue, according to an official at the Harvard-affiliated hospital 
			who asked to remain anonymous. 
			 
			The Alzheimer's Association, which says it supports any legitimate 
			avenue of research that offers hope of a cure, has not received a 
			request to fund a project involving fetal tissue in about seven 
			years, said Maria Carrillo, the association's chief scientific 
			officer. 
			 
			"That tells us the field has really moved to [the newer 
			reprogrammed] cells," she said. 
			 
			STILL VITAL 
			 
			But scientists also said that for some studies, fetal tissue remains 
			essential, and that efforts to reduce an already-scarce supply could 
			set back research on birth defects, spinal cord injuries, 
			Parkinson's disease, eye diseases, and vaccines and treatments for 
			HIV/AIDS, to name a few. 
			  
			  
			 
			"No question fetal tissue remains an important research tool," said 
			Sean Tipton of the American Society for Reproductive Medicine. Fetal 
			cells have long been used in vaccine research, and are still used in 
			toxicology studies. 
			 
			Scientists say that newly developed stem cell technologies using 
			adult cells have not yet been fully validated, and they still need 
			to run tests with fetal cells to ensure their quality. 
			 
			Research using human fetal tissue dates back to the 1930s, when 
			fetal kidney cells were used as a medium in which to grow vaccines. 
			Unlike embryonic stem cells, which come from days-old embryos that 
			are capable of becoming any type of cell, fetal stem cells already 
			contain instructions for becoming specialized cells that form 
			organs. 
			 
			Interest in fetal tissue surged in the 1990s with the hope that 
			fetal nerve cells could treat Alzheimer's and Parkinson's. "They 
			gave up on that," said Arthur Caplan, a bioethicist at NYU's Langone 
			Medical Center, because it failed to work. 
			 
			Some research suggests, however, that different methods involving 
			fetal tissue transplants might be more effective. 
			 
			Last year, for example, Harvard Stem Cell Institute reported that 
			neuronal stem cells extracted from fetal tissue and transplanted 
			into the brains of Parkinson's disease patients helped them remain 
			healthy and functional for as long as 14 years. 
			 
			Researchers have also had success using fetal stem cells to treat 
			spinal cord injuries. 
			 
			Insoo Hyun, a bioethicist at Case Western Reserve University, said 
			the newer, lab-derived cells have not been perfected and researchers 
			still need fetal tissue to ensure that the reprogrammed cells are of 
			comparable quality. 
			 
			"People are trying very hard to transition out of using stem cells 
			from fetuses but to make that transition, it will take some time," 
			Hyun said. 
			
            [to top of second column]  | 
            
             
  
				
			In a statement on behalf of its many campuses, the University of 
			California's Office of the President defended continuing research 
			that uses fetal and placental tissue, saying it remains "vital to 
			finding treatments and cures for a wide variety of adult and 
			childhood diseases and medical conditions." 
			 
			One California-based regenerative medicine expert who spoke on 
			condition of anonymity said that lab-manufactured stem cells don’t 
			work for certain kinds of research. 
			 
			The scientist, whose lab was once the subject of a bomb threat 
			because of its research with fetal tissue, said that embryonic stem 
			cells or reprogrammed cells can't make organs, which are needed to 
			understand complex diseases such as multiple myeloma or ALS, 
			commonly called Lou Gehrig's disease, which strikes motor neurons 
			later in life. 
			 
			"For us, to understand any of a number of disease states, we need 
			organs," he said. 
			 
			"If you took away this area of research, you are taking away the 
			hopes of a lot of people who have currently incurable diseases for 
			which this very likely will get us there." 
  
			RENEWED ATTACKS 
			 
			In Washington, lawmakers led by conservative Republicans are 
			using the controversy over the Planned Parenthood videos to renew 
			efforts to defund the organization, which provides a wide range of 
			women’s health services, including abortion. 
			 
			The sting videos have also drawn attention to government funding for 
			fetal tissue research. Last year, the National Institutes of Health 
			spent $76 million for projects meeting the criteria of human fetal 
			tissue research, about 0.2 percent of the overall NIH budget. But 
			officials say that figure might exaggerate the amount of funding 
			going to fetal tissue because grants overlap, and cover multiple 
			aspects of research. 
			 
			Many researchers said they look forward to a time when fetal tissue 
			will be unnecessary. 
			 
			Hyun said that in addition to other concerns, scientists are 
			hampered by the unpredictability of supply when working with fetal 
			tissue. 
			
			  
			“You have to wait around for someone to donate, and you have to use 
			the tissue right away. It's hard to plan your studies,” he said. 
			 
			(Reporting by Julie Steenhuysen; Editing by Eric Effron and Sue 
			Horton) 
			[© 2015 Thomson Reuters. All rights 
				reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  |